NIKKEI 225
38,131.30 -274.36 (-0.71%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.26 -0.67 (-0.82%) GOLD FUTURES
2,303.00 +0.10 (+0.00%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,456.70 -2,728.17 (-5.33%)
AstraZeneca PLC (AZN.L)
| Previous close | 12,024.00 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,990,598 |
| Market cap | 186.989B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 37.34 |
| EPS (TTM) | 3.23 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 2.28 (1.89%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 126.02 |
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
BenzingaAstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in numerous cases. Lawyers representing the plaintiffs argue that the vaccine resulted in side effects for a small number of families, including brain injuries and fatalities. AstraZeneca, while contesting the claims, has acknowledged in court documents that its vaccine can, in rare instances, cause Thro
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
